<SEC-DOCUMENT>0001140361-21-034063.txt : 20211007
<SEC-HEADER>0001140361-21-034063.hdr.sgml : 20211007
<ACCEPTANCE-DATETIME>20211007205634
ACCESSION NUMBER:		0001140361-21-034063
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20211007
FILED AS OF DATE:		20211007
DATE AS OF CHANGE:		20211007

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Chin Mark
		CENTRAL INDEX KEY:			0001734389

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40881
		FILM NUMBER:		211313657

	MAIL ADDRESS:	
		STREET 1:		20 BERKELEY SQUARE, MAYFAIR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1J 6EQ

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pyxis Oncology, Inc.
		CENTRAL INDEX KEY:			0001782223
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831160910
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		800 BOYLSTON STREET
		STREET 2:		SUITE 1555
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02199
		BUSINESS PHONE:		(617) 351-2575

	MAIL ADDRESS:	
		STREET 1:		800 BOYLSTON STREET
		STREET 2:		SUITE 1555
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02199
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-10-07</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001782223</issuerCik>
        <issuerName>Pyxis Oncology, Inc.</issuerName>
        <issuerTradingSymbol>PYXS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001734389</rptOwnerCik>
            <rptOwnerName>Chin Mark</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PYXIS ONCOLOGY, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>35 CAMBRIDGEPARK DRIVE</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02140</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series B Convertible Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1433261</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.71</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-08-18</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>15725</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each 6.359 shares of Series B Convertible Preferred Stock are currently convertible into one share of Common Stock at the option of the holder, for no additional consideration, and will convert automatically upon completion of the Issuer's initial public offering (with fractional shares paid out in cash).  These shares have no expiration date.</footnote>
        <footnote id="F2">These securities are held directly by Arix Bioscience Holdings Limited (&quot;Arix&quot;). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix.  The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.</footnote>
        <footnote id="F3">These stock options vest in three, substantially-equal annual installments beginning on the first anniversary of the August 19, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.</footnote>
    </footnotes>

    <remarks>Exhibit List: Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Pamela Connealy, Attorney-in-Fact for Mark Chin</signatureName>
        <signatureDate>2021-10-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>brhc10029694_ex-24.htm
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">POWER OF ATTORNEY</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of <u>Pamela Connealy</u> and <u>Jitendra Wadhane</u>, or either of them acting individually, and with full power of
      substitution, the undersigned's true and lawful attorney-in-fact to:</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e11aac83a7f4b5988b18fe84e1c6e1f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 27pt;"><br>
          </td>
          <td style="width: 31.5pt; vertical-align: top; align: right; color: #1F1F1F;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #1F1F1F;">prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form
              ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange
              Act of 1934 or any rule or regulation of the SEC;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z17b5792077374489b027e3a3ba6c0686" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 27pt;"><br>
          </td>
          <td style="width: 31.5pt; vertical-align: top; align: right; color: #1F1F1F;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div><font style="color: #1F1F1F;">execute for and on behalf of the undersigned, in the undersigned's capacity
                as an officer and/or director of </font>Pyxis Oncology, Inc., <font style="color: #1F1F1F;">a Delaware corporation (the "Company"), Forms 3, 4, and 5, including amendments
                thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations thereunder;</font></div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z030b6e7f39f84141a53d4d25c90e36c1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 27pt;"><br>
          </td>
          <td style="width: 31.5pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #1F1F1F;">do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or
              5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z45d4ce71837a421ab82fa26cab49b78d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 27pt;"><br>
          </td>
          <td style="width: 31.5pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #1F1F1F;">take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in
              the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain
              such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: #1F1F1F;">The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act
      and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of
      substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers
      herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with
      Section 16 of the Securities Exchange Act of 1934.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><font style="color: #1F1F1F;">This Power of Attorney shall remain in full
        force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier (a) revoked by the undersigned </font><font style="color: #3F3F3F;">i</font><font style="color: #1F1F1F;">n a signed writing delivered to the foregoing
        attorneys-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined herein at a later date.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><font style="color: #1F1F1F;">IN WITNESS WHEREOF, the undersigned has caused
        this Power of Attorney to be executed as of this </font>15th <font style="color: #1F1F1F;">day of </font>September,<font style="color: #1F1F1F;"> 2021.</font></div>
    <div style="text-indent: 36pt;"><font style="color: #1F1F1F;"> <br>
      </font></div>
    <div style="font-family: 'Times New Roman',Times,serif;"><font style="color: rgb(31, 31, 31);"> </font>
      <table id="za6ed409cace44f5eb622885c0c30a346" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Mark Chin<br>
              </div>
            </td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div style="text-align: center;">&#160;Signature</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">&#160;Mark Chin<br>
              </div>
            </td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div style="text-align: center;">&#160;Print Name<br>
              </div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
